摘要 |
The present application relates a method of predicting the response of HPV positive and HPV negative cancer patients, including HNSCC patients, to a drug, including agents that specifically bind to an EGFr polypeptide. The present application also relates to methods and kits for predicting the usefulness of agents that specifically bind to an EGFr polypeptide in the treatment of cancer, including HNSCC, in HPV positive and negative patients. |